Application of robotics to steady state enzyme kinetics: Analysis of tight-binding inhibitors of dipeptidyl peptidase IV

Analytical Biochemistry

Volumn 321, Issue 2, 2003, Pages 157-166

  Wang, Aiying ^a   Huang, Yanting ^a   Taunk, Prakash ^a   Magnin, David R ^a   Ghosh, Krishnendu ^a   Robertson, James G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Automation; Competitive inhibitor; Dipeptidyl peptidase IV; Drug discovery; Enzyme assay; Isoleucyl 4 cyanothiazolidide; Signal window analysis; Steady state kinetics; Tight binding inhibitor

Indexed keywords

AUTOMATION; ENZYME KINETICS; KINETICS; PURIFICATION;

COMPETITIVE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DRUG DISCOVERY; ENZYME ASSAYS; ISOLEUCYL 4-CYANOTHIAZOLIDIDE; STEADY-STATE KINETICS; TIGHT BINDING; WINDOW ANALYSIS;

ROBOTICS;

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; ISOLEUCYL 4 CYANOTHIAZOLIDIDE; ISOLEUCYLTHIAZOLIDIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL ERROR; ARTICLE; AUTOMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; ENZYME SUBSTRATE COMPLEX; HUMAN; INSTRUMENTATION; NONHUMAN; PH; PKA; PLASMA; PRIORITY JOURNAL; PROBABILITY; RAT; ROBOTICS; STEADY STATE; SWINE; VALIDATION PROCESS;

SUIDAE;

EID: 0141849198     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(03)00434-2     Document Type: Article

References (39)

1. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964.
2. Heins J., Welker P., Schonlein C., Born I., Hartrodt B., Neubert K., Tsuru D., Barth A. Mechanism of proline-specific proteinases: (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from flavobacterium meningosepticum. Biochim. Biophys. Acta. 954:1988;161-169.
3. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N.H., Kameoka J., Dahlberg H.N., Schlossman S.F., Morimoto C. Cloning and functional expression of the T cell activation antigen CD2. J. Immunol. 149:1992;481-486.
4. Iwaki-Egawa S., Watanabe Y., Kikuya Y., Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J. Biochem. 124:1998;428-433.
5. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E., Norcross M.A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186:1997;1865-1872.
6. Heymann E., Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 91:1978;360-364.
7. Kato T., Nagatsu T., Fukasawa K., Harada M., Nagatsu I., Sakakibara S. Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin by X-Pro dipeptidyl-aminopeptidase. Biochim. Biophys. Acta. 525:1978;417-422.
8. Conlon J.M., Sheehan L. Conversion of substance P to C-terminal fragments in human plasma. Regul. Peptide. 7:1983;335-345.
9. Hartrodt B., Neubert K., Fischer G., Schulz H., Barth A. Synthesis and enzymatic degradation of beta-casomorphin 5. Pharmazie. 37:1982;165-169.
10. Hartrodt B., Neubert K., Fischer G., Demuth U., Yoshimoto T., Barth A. Degradation of beta-casomorphin-5 by proline-specific-endopeptidase (PSE) and post-proline-cleaving-enzyme (PPCE). Comparative studies of the beta-casomorphin-5 cleavage by dipeptidyl-peptidase IV. Pharmazie. 37:1982;72-73.
11. Kreil G., Umbach M., Brantl V., Teschemacher H. Studies on the enzymatic degradation of β-casomorphins. Life Sci. 33:1983;137-140.
12. Mentlein R., Heymann E. Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers. Arch. Biochem. Biophys. 217:1982;748-750.
13. Hinke S.A., Pospisilik J.A., Demuth H.-U., Mannhart S., Kuhn-Wache K., Hoffmann T., Nishimura E., Pederson R.A., McIntosh C.H. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J. Biol. Chem. 275:2000;3827-3834.
14. Frohman L.A., Downs T.R., Heimer E.P., Felix A.M. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83:1989;1533-1540.
15. Kreil G., Haiml L., Suchanek G. Stepwise cleavage of the pro part of promelittin by dipeptidylpeptidase IV. Evidence for a new type of precursor-product conversion. Eur. J. Biochem. 111:1980;49-58.
16. Boman H.C., Boman I.A., Andreu D., Li Z., Merrifield R.B., Schlenstedt G., Zimmermann R. Chemical synthesis and enzymic processing of precursor forms of cecropins A and B. J. Biol. Chem. 264:1989;5852-5860.
17. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
18. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 161:1998;55-70.
19. Miyamoto Y., Ganapathy V., Barlas A., Neubert K., Barth A., Leibach F.H. Role of dipeptidyl peptidase IV in uptake of peptide nitrogen from β-casomorphin in rabbit renal BBMV. Am. J. Physiol. 252:1987;F670-F677.
20. Pauly R.P., Demuth H.-U., Rosche F., Schmidt J., White H.A., Lynn F., McIntosh C.H.S., Pederson R.A. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism. 48:1999;385-389.
21. Pederson R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H., Demuth H.-U. Improved glucose tolerance in zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
22. Li J., Wilk E., Wilk S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch. Biochem. Biophys. 323:1995;148-154.
23. Gutheil W.G., Bachovchin W.W. Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. Biochemistry. 32:1993;8723-8731.
24. Steinmetzer T., Silberring J., Mrestani-Klaus C., Fittkau S., Barth A., Demuth H.-U. Peptidyl ammonium methyl ketones as substrate analog inhibitors of proline-specific peptidases. J. Enzyme Inhib. 7:1993;77-85.
25. Belyaev A., Zhang X., Augustyns K., Lambeir A.-M., De Meester I., Vedernikova I., Scharpe S., Haemers A. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem. 42:1999;1041-1052.
26. Nguyen C., Blanco J., Mazaleyrat J.-P., Krust B., Callebaut C., Jacotot E., Hovanessian A.G., Wakselman M. Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26. J. Med. Chem. 41:1998;2100-2110.
27. Heins J., Neubert K., Barth A., Canizaro P.C., Behal F.J. Kinetic investigation of the hydrolysis of aminoacyl p-nitroanilides by dipeptidyl peptidase IV from human and pig kidney. Biochim. Biophys. Acta. 785:1984;30-35.
28. Pace C.N., Vajdos F., Fee L., Grimsley G., Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:1995;2411-2423.
29. Duggleby R.G. Regression analysis of nonlinear Arrhenius plots: an empirical model and a computer program. Comput. Biol. Med. 14:1984;447-455.
30. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:1999;67-73.
31. Ashworth D.M., Atrash B., Baker G.R., Baxter A.J., Jenkins P.D., Jones D.M., Szelke M. 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 6:1996;2745-2748.
32. Ashworth D.M., Atrash B., Baker G.R., Baxter A.J., Jenkins P.D., Jones D.M., Szelke M. 2-Cyanopyrrolidides as very potent stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 6:1996;1163-1166.
33. Cha S. Tight-binding inhibitors-I. Kinetic behavior. Biochem. Pharmacol. 24:1975;2177-2185.
34. Cheng Y.C., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
35. Chou T.C. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol. Pharmacol. 10:1974;235-247.
36. Cleland W.W. The use of pH studies to determine chemical mechanisms of enzyme-catalyzed reactions. Methods Enzymol. 87:1982;390-405.
37. Christopherson R.I., Duggleby R.G. Metabolic resistance: the protection of enzymes against drugs which are tight-binding inhibitors by the accumulation of substrates. Eur. J. Biochem. 134:1983;331-335.
38. DeMuth H.-U. Recent developments in inhibiting cysteine and serine proteases. J. Enzyme Inhib. 3:1990;249-278.
39. Durinx C., Lambeir A.M., Bosmans E., Falmagne J.B., Berghmans R., Haemers A., Scharpe S., De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267:2000;5608-5613.